Eli Lilly Quick Ratio 2010-2025 | LLY

Historical quick ratio values for Eli Lilly (LLY) over the last 10 years.
Eli Lilly Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2025-03-31 $31.95B $30.07B 1.06
2024-12-31 $25.15B $28.38B 0.89
2024-09-30 $23.96B $24.67B 0.97
2024-06-30 $23.72B $27.12B 0.88
2024-03-31 $19.09B $18.60B 1.03
2023-12-31 $19.95B $27.29B 0.73
2023-09-30 $18.11B $22.00B 0.82
2023-06-30 $16.53B $18.92B 0.87
2023-03-31 $16.27B $16.01B 1.02
2022-12-31 $13.73B $17.14B 0.80
2022-09-30 $13.81B $15.65B 0.88
2022-06-30 $13.22B $15.62B 0.85
2022-03-31 $13.07B $13.39B 0.98
2021-12-31 $14.57B $15.05B 0.97
2021-09-30 $13.90B $13.68B 1.02
2021-06-30 $13.47B $15.09B 0.89
2021-03-31 $12.94B $11.71B 1.11
2020-12-31 $13.48B $12.48B 1.08
2020-09-30 $12.69B $11.98B 1.06
2020-06-30 $11.27B $11.99B 0.94
2020-03-31 $10.89B $12.61B 0.86
2019-12-31 $10.52B $11.78B 0.89
2019-09-30 $9.56B $10.83B 0.88
2019-06-30 $10.27B $11.86B 0.87
2019-03-31 $9.54B $11.24B 0.85
2018-12-31 $17.45B $11.89B 1.47
2018-09-30 $16.57B $10.83B 1.53
2018-06-30 $14.18B $13.06B 1.09
2018-03-31 $11.63B $11.55B 1.01
2017-12-31 $14.74B $14.54B 1.01
2017-09-30 $13.02B $12.67B 1.03
2017-06-30 $11.40B $11.30B 1.01
2017-03-31 $8.94B $10.45B 0.86
2016-12-31 $11.54B $10.99B 1.05
2016-09-30 $9.51B $8.27B 1.15
2016-06-30 $9.22B $8.40B 1.10
2016-03-31 $7.97B $7.34B 1.09
2015-12-31 $9.13B $8.23B 1.11
2015-09-30 $9.15B $8.30B 1.10
2015-06-30 $9.06B $8.23B 1.10
2015-03-31 $8.76B $8.34B 1.05
2014-12-31 $9.19B $9.74B 0.94
2014-09-30 $9.27B $7.58B 1.22
2014-06-30 $9.97B $7.42B 1.34
2014-03-31 $10.07B $6.63B 1.52
2013-12-31 $10.18B $8.92B 1.14
2013-09-30 $10.23B $8.08B 1.27
2013-06-30 $9.91B $8.41B 1.18
2013-03-31 $9.75B $7.59B 1.28
2012-12-31 $10.40B $8.39B 1.24
2012-09-30 $11.49B $6.96B 1.65
2012-06-30 $9.99B $6.61B 1.51
2012-03-31 $10.18B $6.55B 1.55
2011-12-31 $11.95B $8.93B 1.34
2011-09-30 $12.06B $8.22B 1.47
2011-06-30 $12.08B $8.62B 1.40
2011-03-31 $12.59B $7.65B 1.65
2010-12-31 $12.32B $6.93B 1.78
2010-09-30 $11.51B $6.10B 1.89
2010-06-30 $10.29B $6.33B 1.63
2010-03-31 $9.78B $5.66B 1.73
2009-12-31 $9.64B $6.57B 1.47
2009-09-30 $8.68B $6.07B 1.43
2009-06-30 $7.94B $6.99B 1.14
2009-03-31 $7.71B $7.36B 1.05
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $729.643B $45.043B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $373.014B 15.43
AbbVie (ABBV) United States $335.316B 18.48
Roche Holding AG (RHHBY) Switzerland $260.602B 0.00
Novartis AG (NVS) Switzerland $249.308B 14.24
Merck (MRK) United States $198.296B 10.14
Pfizer (PFE) United States $132.753B 7.27
Sanofi (SNY) France $123.776B 12.19
Bayer (BAYRY) Germany $29.826B 6.07
Innoviva (INVA) United States $1.355B 14.20
Novo Nordisk (NVO) Denmark $0.000B 22.08